A detailed history of Black Rock Inc. transactions in Enochian Biosciences Inc stock. As of the latest transaction made, Black Rock Inc. holds 3,656,954 shares of ENOB stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,656,954
Previous 314,314 1063.47%
Holding current value
$16.8 Million
Previous $1.45 Million 1064.08%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
N/A
3,342,640 Added 1063.47%
3,656,954 $16.8 Million
Q1 2024

May 10, 2024

BUY
N/A
9,658 Added 3.17%
314,314 $1.45 Million
Q4 2023

Feb 13, 2024

BUY
$4.3 - $4.7 $91,104 - $99,578
21,187 Added 7.47%
304,656 $1.4 Million
Q3 2023

Nov 13, 2023

BUY
$0.0 - $4.46 $0 - $136,975
30,712 Added 12.15%
283,469 $1.26 Million
Q2 2023

Aug 11, 2023

SELL
$0.4 - $1.3 $391,690 - $1.27 Million
-979,227 Reduced 79.48%
252,757 $144,000
Q1 2023

May 12, 2023

BUY
$0.91 - $1.31 $140,816 - $202,713
154,743 Added 14.36%
1,231,984 $1.13 Million
Q4 2022

Feb 13, 2023

BUY
$1.03 - $2.13 $35,874 - $74,187
34,830 Added 3.34%
1,077,241 $1.11 Million
Q3 2022

Nov 14, 2022

SELL
$1.7 - $2.86 $23,910 - $40,225
-14,065 Reduced 1.33%
1,042,411 $1.89 Million
Q2 2022

Aug 12, 2022

BUY
$1.93 - $8.73 $1.65 Million - $7.48 Million
856,390 Added 428.01%
1,056,476 $2.04 Million
Q1 2022

May 12, 2022

BUY
$4.42 - $9.0 $40,040 - $81,531
9,059 Added 4.74%
200,086 $1.65 Million
Q4 2021

Feb 10, 2022

BUY
$6.71 - $12.55 $643,374 - $1.2 Million
95,883 Added 100.78%
191,027 $1.39 Million
Q3 2021

Nov 09, 2021

SELL
$4.56 - $7.88 $215,587 - $372,550
-47,278 Reduced 33.2%
95,144 $640,000
Q2 2021

Aug 11, 2021

BUY
$2.94 - $6.79 $418,720 - $967,045
142,422 New
142,422 $707,000

Others Institutions Holding ENOB

About Enochian Biosciences Inc


  • Ticker ENOB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,950,000
  • Market Cap $244M
  • Description
  • Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for au...
More about ENOB
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.